News
NEO
14.17
+3.20%
0.44
The Disinflation Trade Has A New Address: Genomics
Seeking Alpha · 1d ago
NeoGenomics director Carolyn S. Starrett files initial beneficial ownership statement
PUBT · 2d ago
NeoGenomics Adds Data-Focused Independent Director to Board
TipRanks · 2d ago
NeoGenomics appoints Flatiron Health ex-CEO Carolyn Starrett to board
PUBT · 2d ago
NEOGENOMICS APPOINTS CAROLYN STARRETT TO ITS BOARD OF DIRECTORS
Reuters · 2d ago
NeoGenomics Announces New Convertible Notes and Share Buyback
TipRanks · 5d ago
NeoGenomics prices USD 316.25 million 0.75% convertible notes due 2032
PUBT · 5d ago
Weekly Report: what happened at NEO last week (0615-0619)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Ocular Therapeutix (OCUL)
TipRanks · 06/18 09:10
NeoGenomics Insider Move: Director’s Share Sale Sparks Fresh Market Buzz
TipRanks · 06/18 02:09
NeoGenomics director Lynn A. Tetrault sells 5,307 shares worth $58,907.7
PUBT · 06/17 20:08
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
Reuters · 06/17 15:42
BUZZ-NeoGenomics rebounds after $275 mln convertible debt sale
Reuters · 06/17 14:46
NeoGenomics announces pricing of $275M convertible senior notes offering
TipRanks · 06/17 12:22
NeoGenomics Prices New 2032 Convertible Senior Notes Offering
TipRanks · 06/17 10:35
NeoGenomics prices $275M convertible notes due 2032, plans repurchases of 2028 notes and shares
Seeking Alpha · 06/17 10:28
NeoGenomics Prices Offering Of $275M Of 0.75% Convertible Senior Notes Due 2032
Benzinga · 06/17 10:17
NeoGenomics prices USD 275 million convertible senior notes due 2032 offering
PUBT · 06/17 10:01
NEOGENOMICS - SOME PROCEEDS, WITH CASH, MAY BE USED TO REPURCHASE UP TO $25 MLN OF OUTSTANDING COMMON STOCK
Reuters · 06/17 10:00
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
Barchart · 06/17 05:00
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.